Skip to content

Bolt CSP-M Holter Study

Intracardiac Electrical Characteristics of LBBAP

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06540521
Enrollment
75
Registered
2024-08-06
Start date
2024-08-13
Completion date
2026-06-30
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bradycardia, Heart Failure

Keywords

LBBAP, LBBP, LVSP

Brief summary

The purpose of this study is to investigate the cardiac electrical characteristics in different pacing outputs and body positions in LBB area pacing (LBBAP), from which the findings may help to develop and support data validation of a novel algorithm for LBB capture determination for LBBAP.

Detailed description

Among LBB area pacing (LBBAP), it has been reported that left ventricular (LV) septal pacing (LVSP), which refers to a pacing approach that only captures the LV septal myocardium, produces homogeneous electrical propagation in the septum and leads to delayed LV lateral wall activation. Although large randomized trials are lacking, small observational studies have shown more preserved physiological ventricular depolarization, or superior electrical and mechanical synchrony of the LBB capture over LVSP. During the implantation of a device, the most commonly used method to distinguish LVSP from the LBB capture is to pace with different pacing outputs. A transition will be found in the ECG morphology with changes in the LV activation time if the pacing capture threshold (PCT) of the local myocardium is different from that of the LBB (i.e., LBB-PCT), indicating a transition between capturing the LBB and LVSP without any LBB capture. So far, there is no systematic investigation on the EGM characteristics or correlation between ECG and EGM characteristics at different conduction system capture status. Findings from this study will help to better characterize EGM characteristics and to develop an optimal LBBAP modality to differentiate LBB capture.

Interventions

OTHERNo intervention

No intervention

Sponsors

Medtronic Cardiac Rhythm and Heart Failure
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged \>=18 years * Patients who are willing to provide Informed Consent * Patients who have received LBBAP therapy \>= 1 month for 1 to 4 months (including 1 and 4 month) * Patients implanted with a single/dual-chamber pacemaker or a CRT-P with LBBAP lead connected to RV port * Implanted device can provide at least 3-channel real-time intracardiac electrogram

Exclusion criteria

* Patients who are pregnant or have a plan for pregnancy during the study * Patients who have medical conditions that would limit study participation * Patients who were already enrolled in clinical trial(s) which would impact study participation

Design outcomes

Primary

MeasureTime frameDescription
Intracardiac electrical characteristics in different pacing outputs.received LBBAP therapy >= 1 month for 1 to 4 months (including 1 and 4 month); and an optional follow-up 6 month after the enrollment12-lead ECG and LBBAP EGM characteristics and duration in different pacing outputs.

Secondary

MeasureTime frameDescription
Intracardiac electrical characteristics under different body position.received LBBAP therapy >= 1 month for 1 to 4 months (including 1 and 4 month); and an optional follow-up 6 month after the enrollment12-lead ECG and LBBAP EGM characteristics and duration under different body positions.
The correlation between LBB capture status and LBBAP EGM characteristicsreceived LBBAP therapy >= 1 month for 1 to 4 months (including 1 and 4 month); and an optional follow-up 6 month after the enrollmentECG and EGM characteristics in different LBB capture status

Countries

China

Contacts

Primary ContactSimon Cao, PhD
Simon.cao@medtronic.com862133230325

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026